Arrowhead Pharmaceuticals ( $ARWR ) Declines -25.65% Over 30 Days Despite Strong Clinical Pipeline (See the latest news for any ticker on Tickeron.) Arrowhead Pharmaceuticals (ARWR) fell about 25.65% over the trailing 30 days, from a close of $89.41 to $66.48, despite a steady stream of positive clinical updates. The decline followed a powerful rally, with the stock still up more than 110% over the trailing 12 months, underscoring profit-taking and fading short-term momentum. $AXON $IONS $REPL $AMRN $AVBP
published
Arrowhead Pharmaceuticals ( $ARWR ) Declines -25.65% Over 30 Days Despite Strong Clinical Pipeline (See the latest news for any ticker on Tickeron.) Arrowhead Pharmaceuticals (ARWR) fell about 25.65% over the trailing 30 days, from a close of $89.41 to $66.48,
$ARWR$AXON$IONS$REPL$AMRN$AVBP
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.
